End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.

Hsin-Fu LeeLai-Chu SeeYi-Hsin ChanYung-Hsin YehLung-Sheng WuJia-Rou LiuHui-Tzu TuChun-Li WangChi-Tai KuoShang-Hung Chang

Published in: Internal medicine journal (2019)

In this large-scale, population-based cohort study, ESRD patients using ACEI/ARB had a lower risk of CV death and all-cause mortality than non-users did.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
angiotensin converting enzyme
angiotensin ii
prognostic factors
cardiovascular disease
risk factors
coronary artery disease
patient reported